Incyte Stock

Incyte Revenue

The The revenue of Incyte (INCY) as of Aug 14, 2026 is 5.14 B USD. In the previous year, The revenue was 4.24 B USD — a change of 21.22% (higher).

Revenue

5.14 BUSD

YoY

21.22%

Last updated:

In 2026, Incyte's sales reached 5.14 B USD, a 21.22% difference from the 4.24 B USD sales recorded in the previous year.

Over the last 19 years Incyte grew revenue by 31.7% annually, reaching 5.14 B USD.

The Incyte Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B USD)
GROSS MARGIN (%)
Date
REVENUE (B USD)
GROSS MARGIN (%)
Jan 1, 2023
3.70 base
93.10 base
Jan 1, 2024
4.24 base
92.64 base
Jan 1, 2025
5.14 base
92.76 base
Jan 1, 2026 (e)
5.94 base
80.25 base
Jan 1, 2027 (e)
6.26 base
76.24 base
Jan 1, 2028 (e)
6.51 base
73.22 base
Jan 1, 2029 (e)
4.68 base
101.90 base
Jan 1, 2030 (e)
4.87 base
98.02 base
YEARREVENUE (B USD)GROSS MARGIN (%)
2030 est 4.8798.02
2029 est 4.68101.90
2028 est 6.5173.22
2027 est 6.2676.24
2026 est 5.9480.25
2025 5.1492.76
2024 4.2492.64
2023 3.7093.10
2022 3.3993.90
2021 2.9994.94
2020 2.6795.08
2019 2.1694.71
2018 1.8895.00
2017 1.5494.83
2016 1.1194.74
2015 0.7596.42
2014 0.5199.41
2013 0.3599.82
2012 0.3099.95
2011 0.09100.00
2010 0.17100.00
2009 0.01100.00
2008 0.00100.00
2007 0.03100.00
2006 0.03100.00
Access this data via the Eulerpool API

Incyte Revenue

Incyte Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.70 B USD
655.36 M USD
597.60 M USD
Jan 1, 2024
4.24 B USD
101.29 M USD
32.62 M USD
Jan 1, 2025
5.14 B USD
1.34 B USD
1.29 B USD
Jan 1, 2026 (e)
5.94 B USD
1.12 B USD
713.59 M USD
Jan 1, 2027 (e)
6.26 B USD
1.21 B USD
1.78 B USD
Jan 1, 2028 (e)
6.51 B USD
1.27 B USD
1.94 B USD
Jan 1, 2029 (e)
4.68 B USD
911.80 M USD
759.42 M USD
Jan 1, 2030 (e)
4.87 B USD
947.89 M USD
866.48 M USD

Incyte Margins

Incyte stock margins

The Incyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Incyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Incyte.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
93.10 %
17.73 %
16.17 %
Jan 1, 2024
92.64 %
2.39 %
0.77 %
Jan 1, 2025
92.76 %
26.12 %
25.03 %
Jan 1, 2026 (e)
92.76 %
18.81 %
12.01 %
Jan 1, 2027 (e)
92.76 %
19.28 %
28.50 %
Jan 1, 2028 (e)
92.76 %
19.48 %
29.81 %
Jan 1, 2029 (e)
92.76 %
19.48 %
16.23 %
Jan 1, 2030 (e)
92.76 %
19.48 %
17.81 %

Incyte Stock analysis

What does Incyte do? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Incyte's Sales Figures

The sales figures of Incyte originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Incyte’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Incyte's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Incyte’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Incyte stock

The revenue of Incyte is 5.14 B USD in 2026.

The revenue of Incyte changed from 4.24 B USD to 5.14 B USD, representing a 21.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Incyte since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Incyte historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Incyte

All Key Metrics — Incyte